A Beacon of Light on Your Cancer Care Journey


Current Trials

ECHO Open to Acrrual Clinical Trials
Updated: 2/21/19

Bladder / Urothelial


ATLAS / Clovis / CO-338-085
A Phase 2, Open-Label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Non Muscle Invasive
Quil t-3.032 : A Multicenter Clinical Trial oflntravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Breast Cancer

MSK 17-585
Phase lb / II Study of Capecitabine 7/7 Schedule with Neratinib in Patients with metastatic fIER2-Positive Breast Cancer

A Phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of Ribociclib with endocrine therapy as an adjuvant  treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant Trial with Ribociclib [LEEOl l]: NATALEE)


NRG-GI004 / SWOG-S1610
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6 / Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer


Alchemist Trials Adjuvant Trials for completely resected patients EGFR or ALK positive

Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist)

Randomized double blind Placebo controlled study of Erlotinib or Placebo in patients with completely resected Epidermal growth factor receptor (EGFR) mutant non­ smallcell lung cancer (NSCLC)

A phase III double-blind trial for surgically resected early stage Non-Small Cell Lung cancer: Crizotinib versus Placebo for pateints with tumors harboring the Anaplastic Lymphoma Kinase (ALK) fusion protein
First Line Metastatic

B-Fast: Blood-First Assay Screening Trial , Umbrella Study
***Cohort A & B Closed***

A Phase II Randomized, Multi- center , Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients  whose  Disease has not Progressed Following Standard of care Platinum-Based Chemotherapy with Durvaluab in First-Line Stage IV Non-Small Cell Lung Cancer (Orion)

A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line treatment in Patients with PD-LI Expressing Advanced Non-Small Cell Lung Cancer


Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

Ovarian Cancer

****Neoadjuvant Subgroup is closed****
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin and Bevacizumab to Patients with newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer


MSK 16-1066
Pilot Study of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban, to treat or prevent thromboembolic events, for advanced Pancreatic Adencarcinoma

Prostate Cancer

D081SC00001 / Propel
A randomized double-blind, Placebo-controlled, multicenter phase III study of Olaparib plus Abiraterone relative to Placebo plus Abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer

For more information on clinical trials, please contact research@echoassociates.org.